Today: 20 December 2025
Subscribe
Browse Category

NYSE:JNJ News 11 December 2025 - 20 December 2025

Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson (NYSE: JNJ) ended Friday’s regular session lower, but the stock moved modestly higher in after-hours trading as investors digested a busy late-day news flow—ranging from Washington drug-pricing headlines to fresh analyst targets and new litigation developments. As
20 December 2025
 ·  ·  ·  ·  · 
Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson (NYSE: JNJ) finished Thursday’s regular session lower even as the broader market moved higher, then ticked modestly upward in after-hours trading—leaving investors with a familiar year-end setup: solid pipeline/MedTech progress on one side, and talc litigation headlines
19 December 2025
 ·  ·  ·  ·  · 
Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson (NYSE: JNJ) ended Wednesday’s session modestly higher—an eye-catching show of relative strength on a down day for major U.S. indexes—while investors digested a fresh FDA approval tied to the company’s lung cancer franchise and looked ahead to
18 December 2025
 ·  ·  ·  ·  · 
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

CAs of Wednesday, December 17, 2025, Johnson & Johnson (NYSE: JNJ) is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation
17 December 2025
 ·  ·  ·  ·  · 
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

(SEO): Johnson & Johnson (NYSE: JNJ) climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3 Johnson & Johnson stock (NYSE: JNJ) capped a volatile but decisively positive week by closing
13 December 2025
 ·  ·  ·  ·  · 
Johnson & Johnson (JNJ) Stock Hits New High After the Bell on December 11, 2025 – What to Know Before the December 12 Open

Johnson & Johnson (JNJ) Stock Hits New High After the Bell on December 11, 2025 – What to Know Before the December 12 Open

Johnson & Johnson (NYSE: JNJ) closed regular trading on Thursday, December 11, 2025 at $210.01, up about 1.7% on the day, marking a fresh 52‑week high before easing slightly in after‑hours trading around $209.25. MarketScreener+1 That move capped a week
12 December 2025
 ·  ·  ·  ·  · 
1 2 3 4
Go toTop